logo

Stock Screener

Forex Screener

Crypto Screener

QGEN

Qiagen N.V. (QGEN)

$

47.53

-0.81 (-1.70%)


Key metrics

Financial statements

Free cash flow per share

Free cash flow per share

2.3037

Market cap

Market cap

10.3 Billion

Price to sales ratio

Price to sales ratio

5.1391

Debt to equity

Debt to equity

0.4133

Current ratio

Current ratio

3.3715

Income quality

Income quality

7.2613

Average inventory

Average inventory

280.3 Million

ROE

ROE

0.0269



Technology

Technology

Technology – consumer electronics

Largecap

Largecap

With a market cap of 121,78 bil stock is ranked 1

Low risk

Low risk

ISS score of this stock is ranked 1


Company description

Profile

QIAGEN N.V. offers comprehensive sample to insight solutions that facilitate the transformation of biological materials into valuable molecular insights globally. The company provides a range of primary sample technology consumables, including nucleic acid stabilization and purification kits tailored for primary sample materials. It supports both manual and automated processing for various applications such as genotyping, gene expression analysis, and the study of viral and bacterial samples, utilizing advanced technologies like silica membranes and magnetic beads. Additionally, QIAGEN supplies secondary sample technology consumables that include kits and components for nucleic acid purification from secondary samples. The company's product offerings extend to instruments for nucleic acid purification, various accessories, and specialized assays including interferon-gamma release assays for TB testing, post-transplant testing assays, and viral load monitoring. QIAGEN also offers prenatal testing solutions, assays for detecting sexually transmitted diseases and HPV, as well as genomic variant analysis methods that identify mutations, insertions, deletions, and fusions. The sample to insight instruments feature one-step molecular analyses designed for complex syndromes and integrated PCR testing. The company provides a multitude of PCR consumables, including quantitative PCR and reverse transcription kits furthering analysis in areas like gene expression and regulation. Moreover, QIAGEN caters to human identification and forensics with STR assays, alongside food contamination testing. Its PCR instrument line includes innovative digital PCR solutions and tailored OEM consumables. Additionally, the company provides predefined and custom NGS gene panels, library preparation kits, and services for whole genome amplification, along with various bioinformatics solutions and custom laboratory services. Recently, the company reported selling, general, and administrative expenses of $564,361,000.00 indicating its operational overhead costs. Meanwhile, it recorded a net income of $83,591,000.00 which reflects its profitability. This performance is supported by an income before tax ratio of 0.06 demonstrating a solid pre-tax margin. The earnings per share (EPS) is reported at $0.37 highlighting the company's profitability on a per-share basis. Moreover, it recorded a substantial revenue of $1,978,214,000.00 underscoring its strong market presence. The stock is affordable at $47.53 making it an attractive option for budget-conscious investors. With an average trading volume of 1,425,331.00 the stock demonstrates moderate liquidity, appealing to a range of investors. Holding a mid-range market capitalization of $10,292,906,680.00 the company positions itself as a steady performer within the competitive landscape. QIAGEN is a key player in the Medical - Diagnostics & Research industry, significantly contributing to the overall market dynamics and advancements. It belongs to the Healthcare sector, where it drives innovation and fosters growth, reinforcing its role as a leader in molecular diagnostics and related fields.

What is Qiagen N.V. (QGEN)'s current stock price?

The current stock price of Qiagen N.V. (QGEN) is $47.53 as of 2025-07-07. Prices may fluctuate during the trading day. For real-time updates, check your brokerage platform or financial news websites.

Investing in Qiagen N.V. (QGEN) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.

Analysts predict Qiagen N.V. stock to fluctuate between $37.63 (low) and $48.82 (high) in the next 365 days, reflecting market expectations and potential volatility.

As of 2025-07-07, Qiagen N.V.'s market cap is $10,292,906,680, based on 216,556,000 outstanding shares.

Compared to Eli Lilly & Co., Qiagen N.V. has a Lower Market-Cap, indicating a difference in performance.

Qiagen N.V. pays dividends. The current dividend yield is 6.03%, with a payout of $1.26 per share.

To buy Qiagen N.V. (QGEN) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for QGEN. Place an order (Market, Limit, etc.).

The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.

Qiagen N.V.'s last stock split was 35:36 on 2025-01-29.

Revenue: $1,978,214,000 | EPS: $0.37 | Growth: -75.97%.

Visit https://www.qiagen.com/investor-relations for detailed financial reports.

You can explore historical data from here

All-time high: $62.56 (2021-02-08) | All-time low: $36.84 (2023-10-30).

Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.


News

QGEN

businesswire.com

QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate Governance Code indicates that Directors of public companies should not serve more than 12 years for a.

QGEN

zacks.com

QGEN vs. EXAS: Which Stock Is the Better Value Option?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Qiagen (QGEN) and Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?

QGEN

zacks.com

Here's Why Qiagen (QGEN) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

QGEN

zacks.com

Here's Why Qiagen (QGEN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

QGEN

zacks.com

QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock

QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.

QGEN

marketwatch.com

Qiagen and Gencurix Enter Clinical Diagnostics Partnership

The companies said Wednesday the partnership combines Qiagen's QIAcuityDx platform, a digital polymerase chain reaction system, with Gencurix's expertise in assay development for oncology tests.

QGEN

zacks.com

QGEN Stock Rises in After Market Following Partnership With Incyte

QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.

QGEN

zacks.com

Should You Add QIAGEN Stock to Your Portfolio for Now?

QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.

QGEN

zacks.com

Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?

Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?

QGEN

businesswire.com

Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors

NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN's QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurr.

See all news

logo
Stocks, Indicators, Pattern screeners all at one place
Stock Screener
Forex Screener
Crypto Screener